SG11201502748RA - Methods for treatment of alport syndrome - Google Patents
Methods for treatment of alport syndromeInfo
- Publication number
- SG11201502748RA SG11201502748RA SG11201502748RA SG11201502748RA SG11201502748RA SG 11201502748R A SG11201502748R A SG 11201502748RA SG 11201502748R A SG11201502748R A SG 11201502748RA SG 11201502748R A SG11201502748R A SG 11201502748RA SG 11201502748R A SG11201502748R A SG 11201502748RA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- methods
- alport syndrome
- alport
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261711514P | 2012-10-09 | 2012-10-09 | |
| US201361779137P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/063884 WO2014058881A1 (en) | 2012-10-09 | 2013-10-08 | Methods for treatment of alport syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502748RA true SG11201502748RA (en) | 2015-05-28 |
Family
ID=49382663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502748RA SG11201502748RA (en) | 2012-10-09 | 2013-10-08 | Methods for treatment of alport syndrome |
Country Status (35)
| Country | Link |
|---|---|
| US (8) | US9012423B2 (ja) |
| EP (2) | EP3620522B1 (ja) |
| JP (4) | JP6272880B2 (ja) |
| KR (4) | KR102165189B1 (ja) |
| CN (1) | CN104718295B (ja) |
| AR (1) | AR092940A1 (ja) |
| AU (3) | AU2013329427B2 (ja) |
| BR (1) | BR112015007709B1 (ja) |
| CA (1) | CA2885605A1 (ja) |
| CL (1) | CL2015000873A1 (ja) |
| CR (1) | CR20150236A (ja) |
| CY (1) | CY1122479T1 (ja) |
| DK (1) | DK2906698T3 (ja) |
| EA (1) | EA201590711A1 (ja) |
| ES (2) | ES2960488T3 (ja) |
| HK (1) | HK1212378A1 (ja) |
| HR (1) | HRP20191948T1 (ja) |
| HU (1) | HUE045858T2 (ja) |
| IL (2) | IL237768B (ja) |
| LT (1) | LT2906698T (ja) |
| MX (1) | MX356340B (ja) |
| MY (1) | MY183921A (ja) |
| NZ (1) | NZ630596A (ja) |
| PH (1) | PH12015500781A1 (ja) |
| PL (1) | PL2906698T3 (ja) |
| PT (1) | PT2906698T (ja) |
| RS (1) | RS60014B1 (ja) |
| SG (1) | SG11201502748RA (ja) |
| SI (1) | SI2906698T1 (ja) |
| TN (1) | TN2015000099A1 (ja) |
| TW (1) | TWI641388B (ja) |
| UA (1) | UA116639C2 (ja) |
| UY (1) | UY35069A (ja) |
| WO (1) | WO2014058881A1 (ja) |
| ZA (1) | ZA201502087B (ja) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8173611B2 (en) | 2004-11-12 | 2012-05-08 | Asuragen Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| TWI698445B (zh) | 2011-04-25 | 2020-07-11 | 法商賽諾菲公司 | 微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法 |
| JP6322189B2 (ja) | 2012-04-25 | 2018-05-09 | レグルス セラピューティクス インコーポレイテッド | Ｍｉｒ−２１活性を調節するためのマイクロｒｎａ化合物及び方法 |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| EP3060664B1 (en) | 2013-10-25 | 2021-07-07 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| WO2016014781A1 (en) * | 2014-07-25 | 2016-01-28 | Rgdi3, Inc. | Collagen iv replacement |
| EP3182989B1 (en) * | 2014-08-21 | 2021-04-14 | Stealth Biotherapeutics Corp | Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome |
| JP6867945B2 (ja) | 2014-10-03 | 2021-05-12 | コールド スプリング ハーバー ラボラトリー | 核内遺伝子出力の標的とされた増強 |
| WO2017060731A1 (en) | 2015-10-09 | 2017-04-13 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| EP3933041B1 (en) | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant retardation |
| US10953020B2 (en) | 2016-11-08 | 2021-03-23 | Reata Pharmaceuticals, Inc. | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
| EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
| CA3047894A1 (en) * | 2016-12-28 | 2018-07-05 | Daiichi Sankyo Company, Limited | Therapeutic drug for alport's syndrome |
| US20210100828A1 (en) * | 2017-05-04 | 2021-04-08 | Sanofi | Methods for Treatment of Alport Syndrome |
| US20200370058A1 (en) | 2017-06-06 | 2020-11-26 | Zymergen Inc. | A htp genomic engineering platform for improving escherichia coli |
| KR20200026878A (ko) | 2017-06-06 | 2020-03-11 | 지머젠 인코포레이티드 | 균류 균주를 개량하기 위한 htp 게놈 공학 플랫폼 |
| PL3673080T3 (pl) | 2017-08-25 | 2024-03-11 | Stoke Therapeutics, Inc. | Oligomery antysensowne do leczenia stanów i chorób |
| KR20200070367A (ko) * | 2017-10-23 | 2020-06-17 | 스톡 테라퓨틱스, 인크. | 넌센스 매개 rna 분해 기반 병태 및 질환 치료를 위한 안티센스 올리고머 |
| CN113166741A (zh) | 2018-10-31 | 2021-07-23 | 齐默尔根公司 | Dna文库的多重确定性组装 |
| JP2022524043A (ja) | 2019-03-08 | 2022-04-27 | ザイマージェン インコーポレイテッド | 微生物の反復ゲノム編集 |
| US11053515B2 (en) | 2019-03-08 | 2021-07-06 | Zymergen Inc. | Pooled genome editing in microbes |
| KR20230022409A (ko) | 2020-05-11 | 2023-02-15 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머 |
| WO2023217764A1 (en) * | 2022-05-09 | 2023-11-16 | Calliditas Therapeutics Suisse Sa | Nox inhibitors for use in the treatment of alport syndrome |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187084C (zh) * | 1998-05-22 | 2005-02-02 | 博伊斯镇国家研究医院 | α1β1整合蛋白受体抑制剂和TGF－β1抑制剂制备用于治疗肾病的药物组合物的用途 |
| KR100574597B1 (ko) * | 1998-05-22 | 2006-04-28 | 보이스 타운 내셔널 리서치 호스피탈 | α1β1 인테그린 수용체 저해제 및 ＴＧＦ-β1 저해제의신장 질환의 치료용 용도 |
| US20060008817A1 (en) | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
| EP2385123B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| US7585501B2 (en) * | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| US20050124591A1 (en) * | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| ITMI20032528A1 (it) * | 2003-12-19 | 2005-06-20 | Francesco Santangelo | Uso di cistina o di cisteina per la prevenzione e il |
| US7585550B2 (en) | 2004-02-02 | 2009-09-08 | College Of William And Mary | Process for modifying polymeric surfaces using deep UV irradiation |
| EP2471922A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
| EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| JP2008512463A (ja) * | 2004-09-08 | 2008-04-24 | ボーイズ タウン ナショナル リサーチ ホスピタル | マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療 |
| US8173611B2 (en) | 2004-11-12 | 2012-05-08 | Asuragen Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| EP1959012A3 (en) | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
| US6995235B1 (en) | 2005-05-02 | 2006-02-07 | Univation Technologies, Llc | Methods of producing polyolefins and films therefrom |
| DK1931780T3 (en) * | 2005-08-29 | 2016-01-25 | Regulus Therapeutics Inc | Antisense-forbindelser med forøget anti-microrna-aktivitet |
| JP5213723B2 (ja) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ， インコーポレーテッド | マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物 |
| EP3502255A1 (en) | 2006-04-03 | 2019-06-26 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition |
| WO2007112754A2 (en) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
| AU2007303205A1 (en) | 2006-10-03 | 2008-04-10 | Tekmira Pharmaceuticals Corporation | Lipid containing formulations |
| EP2094869B1 (de) | 2006-10-09 | 2012-07-25 | Julius-Maximilians-Universität Würzburg | Microrna (mirna) zur diagnose und therapie von herzerkrankungen |
| AU2007333107A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
| US8048998B2 (en) | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
| WO2008151631A2 (en) | 2007-06-15 | 2008-12-18 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
| CA2691691C (en) * | 2007-06-20 | 2013-09-24 | Seth J. Baum | Compositions and methods of treating chronic kidney disease |
| US8440637B2 (en) | 2007-10-04 | 2013-05-14 | Santaris Pharma A/S | Combination treatment for the treatment of hepatitis C virus infection |
| CN101980712B (zh) | 2007-10-29 | 2015-02-18 | 雷古拉斯治疗公司 | 用于肝癌治疗的靶向微小rna |
| US20110257244A1 (en) | 2008-01-18 | 2011-10-20 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
| NZ587178A (en) | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| WO2010099161A1 (en) | 2009-02-26 | 2010-09-02 | The Ohio State University Research Foundation | Micrornas in never-smokers and related materials and methods |
| AU2010258875A1 (en) | 2009-06-08 | 2012-01-19 | Miragen Therapeutics | Chemical modification motifs for miRNA inhibitors and mimetics |
| WO2011126842A2 (en) * | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
| TWI698445B (zh) | 2011-04-25 | 2020-07-11 | 法商賽諾菲公司 | 微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法 |
| WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
| JP6322189B2 (ja) | 2012-04-25 | 2018-05-09 | レグルス セラピューティクス インコーポレイテッド | Ｍｉｒ−２１活性を調節するためのマイクロｒｎａ化合物及び方法 |
| CA2876180C (en) | 2012-06-21 | 2019-11-19 | MiRagen Therapeutics, Inc. | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
| JP6352269B2 (ja) | 2012-09-26 | 2018-07-04 | ミルクス セラピューティクス アクティーゼルスカブＭｉｒｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａ／Ｓ | オフターゲットプロファイルの改善されたオリゴマー |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
-
2013
- 2013-08-10 UA UAA201504453A patent/UA116639C2/uk unknown
- 2013-10-08 UY UY35069A patent/UY35069A/es not_active Application Discontinuation
- 2013-10-08 TW TW102136388A patent/TWI641388B/zh active
- 2013-10-08 DK DK13777458T patent/DK2906698T3/da active
- 2013-10-08 ES ES19188663T patent/ES2960488T3/es active Active
- 2013-10-08 PL PL13777458T patent/PL2906698T3/pl unknown
- 2013-10-08 MX MX2015004460A patent/MX356340B/es active IP Right Grant
- 2013-10-08 EP EP19188663.9A patent/EP3620522B1/en active Active
- 2013-10-08 US US14/048,827 patent/US9012423B2/en active Active
- 2013-10-08 KR KR1020157009045A patent/KR102165189B1/ko active IP Right Grant
- 2013-10-08 PT PT137774584T patent/PT2906698T/pt unknown
- 2013-10-08 WO PCT/US2013/063884 patent/WO2014058881A1/en active Application Filing
- 2013-10-08 AU AU2013329427A patent/AU2013329427B2/en active Active
- 2013-10-08 ES ES13777458T patent/ES2753174T3/es active Active
- 2013-10-08 JP JP2015535891A patent/JP6272880B2/ja active Active
- 2013-10-08 CN CN201380051249.9A patent/CN104718295B/zh active Active
- 2013-10-08 SG SG11201502748RA patent/SG11201502748RA/en unknown
- 2013-10-08 KR KR1020227000173A patent/KR20220005634A/ko not_active Application Discontinuation
- 2013-10-08 AR ARP130103643A patent/AR092940A1/es not_active Application Discontinuation
- 2013-10-08 EP EP13777458.4A patent/EP2906698B1/en active Active
- 2013-10-08 MY MYPI2015000876A patent/MY183921A/en unknown
- 2013-10-08 BR BR112015007709-9A patent/BR112015007709B1/pt active IP Right Grant
- 2013-10-08 KR KR1020237031594A patent/KR20230136686A/ko active Application Filing
- 2013-10-08 KR KR1020207028577A patent/KR102349184B1/ko active IP Right Grant
- 2013-10-08 SI SI201331597T patent/SI2906698T1/sl unknown
- 2013-10-08 CA CA2885605A patent/CA2885605A1/en active Pending
- 2013-10-08 NZ NZ630596A patent/NZ630596A/en unknown
- 2013-10-08 LT LT13777458T patent/LT2906698T/lt unknown
- 2013-10-08 EA EA201590711A patent/EA201590711A1/ru unknown
- 2013-10-08 HU HUE13777458A patent/HUE045858T2/hu unknown
- 2013-10-08 RS RS20191380A patent/RS60014B1/sr unknown
-
2015
- 2015-03-16 TN TNP2015000099A patent/TN2015000099A1/fr unknown
- 2015-03-16 IL IL237768A patent/IL237768B/en active IP Right Grant
- 2015-03-26 ZA ZA2015/02087A patent/ZA201502087B/en unknown
- 2015-04-02 US US14/677,387 patent/US9359609B2/en active Active
- 2015-04-07 CL CL2015000873A patent/CL2015000873A1/es unknown
- 2015-04-08 PH PH12015500781A patent/PH12015500781A1/en unknown
- 2015-05-07 CR CR20150236A patent/CR20150236A/es unknown
-
2016
- 2016-01-06 HK HK16100081.2A patent/HK1212378A1/xx unknown
- 2016-05-10 US US15/151,290 patent/US9688986B2/en active Active
-
2017
- 2017-05-26 US US15/606,554 patent/US9970011B2/en active Active
- 2017-12-28 JP JP2017253345A patent/JP2018080190A/ja active Pending
-
2018
- 2018-04-09 US US15/948,450 patent/US20180298385A1/en not_active Abandoned
- 2018-10-08 IL IL262200A patent/IL262200A/en unknown
-
2019
- 2019-07-29 AU AU2019210494A patent/AU2019210494A1/en not_active Abandoned
- 2019-10-16 JP JP2019189071A patent/JP2020073479A/ja active Pending
- 2019-10-28 HR HRP20191948TT patent/HRP20191948T1/hr unknown
- 2019-10-30 CY CY20191101129T patent/CY1122479T1/el unknown
-
2020
- 2020-01-21 US US16/747,837 patent/US20200283765A1/en not_active Abandoned
-
2021
- 2021-07-02 US US17/366,796 patent/US20220098582A1/en not_active Abandoned
- 2021-11-18 AU AU2021269404A patent/AU2021269404A1/en active Pending
-
2022
- 2022-05-23 JP JP2022083586A patent/JP2022110140A/ja active Pending
-
2023
- 2023-07-21 US US18/356,404 patent/US20240167032A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191948T1 (hr) | Postupci za liječenje alportovog sindroma | |
| EP2723384A4 (en) | TREATMENT OF PROTEINOPATHIES | |
| EP2717855A4 (en) | PROCESSING METHODS | |
| HK1205759A1 (en) | Treatment of biomass | |
| GB201121950D0 (en) | Treatment process | |
| EP2704731A4 (en) | TREATMENT OF AVIAN ORIGIN | |
| GB201221118D0 (en) | Methods of treatment | |
| GB201216740D0 (en) | Methods of treatment | |
| GB201216748D0 (en) | Methods of treatment | |
| GB201206325D0 (en) | Methods of treatment | |
| GB201206330D0 (en) | Methods of treatment | |
| GB201206326D0 (en) | Methods of treatment | |
| GB201206324D0 (en) | Methods of treatment | |
| GB201110602D0 (en) | Methods of treatment | |
| GB201109737D0 (en) | Methods of treatment | |
| GB201221032D0 (en) | Method of treatment | |
| GB201207894D0 (en) | Method of treatment | |
| GB201205449D0 (en) | Treatment process | |
| GB201105056D0 (en) | Treatment process | |
| GB201102270D0 (en) | Treatment | |
| GB201102268D0 (en) | Treatment | |
| GB201102273D0 (en) | Treatment | |
| GB201102267D0 (en) | Treatment | |
| GB201102263D0 (en) | Treatment | |
| GB201102265D0 (en) | Treatment |